Glen R. Hanson - Publications

Affiliations: 
University of Utah, Salt Lake City, UT 
Area:
Pharmacology, Neuroscience Biology, Molecular Biology

202 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Magee CP, Le BD, Siripathane YH, Wilkins DG, Hanson GR, Fleckenstein AE. Methcathinone decreases dopamine transporter function: Role of protein kinase C. Journal of Neurochemistry. PMID 34320222 DOI: 10.1111/jnc.15483  0.415
2020 Magee CP, German CL, Siripathane YH, Curtis PS, Anderson DJ, Wilkins DG, Hanson GR, Fleckenstein AE. 3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters. The Journal of Pharmacology and Experimental Therapeutics. PMID 32385092 DOI: 10.1124/Jpet.119.264895  0.551
2020 Magee CP, Siripathane YH, Le BD, Hanson GR, Fleckenstein AE. Methcathinone Rapidly Decreases Dopamine Transporter Function: Role of Calcium and Protein Kinase C The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04268  0.386
2016 Barak LS, Bai Y, Peterson S, Evron T, Urs N, Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Chung TD, Rodriguiz RM, Wetsel WC, Thomas JB, Hanson GR, Pinkerton AB, et al. ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse. Acs Chemical Biology. PMID 27119457 DOI: 10.1021/Acschembio.6B00291  0.447
2016 Pittenger ST, Swalve N, Chou S, Smith MD, Hoonakker AJ, Pudiak CM, Fleckenstein AE, Hanson GR, Bevins RA. Sex differences in neurotensin and substance P following nicotine self-administration in rats. Synapse (New York, N.Y.). PMID 27074301 DOI: 10.1002/Syn.21907  0.33
2016 Baladi MG, Nielsen SM, McIntosh JM, Hanson GR, Fleckenstein AE. Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors. Behavioural Pharmacology. PMID 26871405 DOI: 10.1097/Fbp.0000000000000215  0.398
2016 Fricks-Gleason AN, German CL, Hoonakker AJ, Friend DM, Ganesh KK, Carver AS, Hanson GR, Fleckenstein AE, Keefe KA. An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Synapse (New York, N.Y.). PMID 26799527 DOI: 10.1002/Syn.21891  0.531
2015 German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. Pharmacological Reviews. 67: 1005-24. PMID 26408528 DOI: 10.1124/Pr.114.010397  0.467
2015 Vieira-Brock PL, McFadden LM, Nielsen SM, Ellis JD, Walters ET, Stout KA, McIntosh JM, Wilkins DG, Hanson GR, Fleckenstein AE. Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits. The Journal of Pharmacology and Experimental Therapeutics. PMID 26391161 DOI: 10.1124/Jpet.114.221945  0.31
2015 Alburges ME, Hoonakker AJ, Cordova NM, Robson CM, McFadden LM, Martin AL, Hanson GR. Effect of low doses of methamphetamine on rat limbic-related neurotensin systems. Synapse (New York, N.Y.). 69: 396-404. PMID 25963809 DOI: 10.1002/Syn.21829  0.434
2015 McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure. Neuropharmacology. 93: 146-54. PMID 25645392 DOI: 10.1016/J.Neuropharm.2015.01.013  0.439
2015 Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug and Alcohol Dependence. 146: 30-8. PMID 25479916 DOI: 10.1016/J.Drugalcdep.2014.10.027  0.404
2014 Baladi MG, Nielsen SM, Umpierre A, Hanson GR, Fleckenstein AE. Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats. Behavioural Pharmacology. 25: 758-65. PMID 25325290 DOI: 10.1097/Fbp.0000000000000094  0.38
2014 German CL, Alburges ME, Hoonakker AJ, Fleckenstein AE, Hanson GR. Mephedrone alters basal ganglia and limbic dynorphin systems. Synapse (New York, N.Y.). PMID 25155699 DOI: 10.1002/Syn.21778  0.481
2014 Baladi MG, Newman AH, Nielsen SM, Hanson GR, Fleckenstein AE. Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia. European Journal of Pharmacology. 732: 105-10. PMID 24685638 DOI: 10.1016/J.Ejphar.2014.03.023  0.535
2014 German CL, Hoonakker AH, Fleckenstein AE, Hanson GR. Mephedrone alters basal ganglia and limbic neurotensin systems. Journal of Neurochemistry. 130: 402-7. PMID 24678634 DOI: 10.1111/Jnc.12727  0.484
2014 McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE. Methamphetamine self-administration attenuates hippocampal serotonergic deficits: role of brain-derived neurotrophic factor. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 1315-20. PMID 24650575 DOI: 10.1017/S1461145714000327  0.387
2014 Alburges ME, Hoonakker AJ, Cordova NM, Robson CM, McFadden LM, Martin AL, Hanson GR. Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine. Psychopharmacology. 231: 2933-40. PMID 24522333 DOI: 10.1007/S00213-014-3468-7  0.407
2014 German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sciences. 97: 2-8. PMID 23911668 DOI: 10.1016/J.Lfs.2013.07.023  0.317
2013 McFadden LM, Hanson GR, Fleckenstein AE. The effects of methamphetamine self-administration on cortical monoaminergic deficits induced by subsequent high-dose methamphetamine administrations. Synapse (New York, N.Y.). 67: 875-81. PMID 23893609 DOI: 10.1002/Syn.21696  0.381
2013 Hanson GR, Hoonakker AJ, Robson CM, McFadden LM, Frankel PS, Alburges ME. Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat. The Journal of Pharmacology and Experimental Therapeutics. 346: 173-81. PMID 23685547 DOI: 10.1124/Jpet.113.205310  0.483
2012 German CL, Hanson GR, Fleckenstein AE. Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. Journal of Neurochemistry. 123: 288-97. PMID 22804716 DOI: 10.1111/J.1471-4159.2012.07875.X  0.536
2012 McFadden LM, Hunt MM, Vieira-Brock PL, Muehle J, Nielsen SM, Allen SC, Hanson GR, Fleckenstein AE. Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug and Alcohol Dependence. 126: 87-94. PMID 22647900 DOI: 10.1016/J.Drugalcdep.2012.04.020  0.422
2012 Hanson GR, Hoonakker AJ, Alburges ME, McFadden LM, Robson CM, Frankel PS. Response of limbic neurotensin systems to methamphetamine self-administration. Neuroscience. 203: 99-107. PMID 22245499 DOI: 10.1016/J.Neuroscience.2011.12.037  0.467
2012 McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse (New York, N.Y.). 66: 240-5. PMID 22120988 DOI: 10.1002/Syn.21506  0.465
2012 McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. The Journal of Pharmacology and Experimental Therapeutics. 340: 295-303. PMID 22034657 DOI: 10.1124/Jpet.111.188433  0.47
2011 Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. The Journal of Pharmacology and Experimental Therapeutics. 339: 530-6. PMID 21810934 DOI: 10.1124/Jpet.111.184119  0.512
2011 Ellis JD, German CL, Birdsall E, Hanson JE, Crosby MA, Rowley SD, Sawada NA, West JN, Hanson GR, Fleckenstein AE. Ephedrine decreases vesicular monoamine transporter-2 function. Synapse (New York, N.Y.). 65: 449-51. PMID 21370280 DOI: 10.1002/Syn.20896  0.44
2011 Alburges ME, Hoonakker AJ, Horner KA, Fleckenstein AE, Hanson GR. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. Journal of Neurochemistry. 117: 470-8. PMID 21323925 DOI: 10.1111/J.1471-4159.2011.07215.X  0.532
2011 Hadlock GC, Nelson CC, Baucum AJ, Hanson GR, Fleckenstein AE. Ex vivo identification of protein-protein interactions involving the dopamine transporter. Journal of Neuroscience Methods. 196: 303-7. PMID 21291912 DOI: 10.1016/J.Jneumeth.2011.01.023  0.332
2011 McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse (New York, N.Y.). 65: 771-7. PMID 21190217 DOI: 10.1002/Syn.20902  0.41
2011 Frankel PS, Hoonakker AJ, Alburges ME, McDougall JW, McFadden LM, Fleckenstein AE, Hanson GR. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. The Journal of Pharmacology and Experimental Therapeutics. 336: 809-15. PMID 21131268 DOI: 10.1124/Jpet.110.176610  0.468
2010 Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. Journal of Neurochemistry. 115: 325-32. PMID 20649837 DOI: 10.1111/J.1471-4159.2010.06922.X  0.441
2010 Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 335: 207-12. PMID 20622144 DOI: 10.1124/Jpet.110.166660  0.5
2009 Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue. Journal of Neuroscience Methods. 180: 317-20. PMID 19464519 DOI: 10.1016/J.Jneumeth.2009.03.015  0.487
2009 Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment. European Journal of Pharmacology. 607: 68-73. PMID 19326567 DOI: 10.1016/J.Ejphar.2009.01.037  0.527
2009 Hadlock GC, Baucum AJ, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. The Journal of Pharmacology and Experimental Therapeutics. 329: 169-74. PMID 19141713 DOI: 10.1124/Jpet.108.145631  0.508
2009 Farnsworth SJ, Volz TJ, Hanson GR, Fleckenstein AE. Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 328: 807-12. PMID 19038779 DOI: 10.1124/Jpet.108.146159  0.486
2009 Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse (New York, N.Y.). 63: 147-51. PMID 19021208 DOI: 10.1002/Syn.20580  0.51
2009 Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles. Journal of Neuroscience Methods. 177: 177-82. PMID 18992277 DOI: 10.1016/J.Jneumeth.2008.10.004  0.438
2009 Alburges ME, Frankel PS, Hoonakker AJ, Hanson GR. Responses of limbic and extrapyramidal substance P systems to nicotine treatment. Psychopharmacology. 201: 517-27. PMID 18773198 DOI: 10.1007/S00213-008-1316-3  0.406
2009 Fleckenstein AE, Volz TJ, Hanson GR. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology. 56: 133-8. PMID 18662707 DOI: 10.1016/J.Neuropharm.2008.07.002  0.488
2008 Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of Methamphetamine Addiction: An Update Substance Abuse. 29: 31-49. PMID 19042205 DOI: 10.1080/08897070802218554  0.371
2008 Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity. Annals of the New York Academy of Sciences. 1139: 285-90. PMID 18991873 DOI: 10.1196/Annals.1432.012  0.445
2008 Frankel PS, Hoonakker AJ, Hanson GR. Differential response of neurotensin to methamphetamine self-administration. Annals of the New York Academy of Sciences. 1139: 112-7. PMID 18991855 DOI: 10.1196/Annals.1432.019  0.442
2008 Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, Fleckenstein AE. Differential regional effects of methamphetamine on dopamine transport. European Journal of Pharmacology. 590: 105-10. PMID 18599036 DOI: 10.1016/J.Ejphar.2008.05.028  0.541
2008 Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 327: 161-7. PMID 18591219 DOI: 10.1124/Jpet.108.139386  0.482
2008 Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology. 55: 41-6. PMID 18538358 DOI: 10.1016/J.Neuropharm.2008.04.019  0.406
2007 Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. The Journal of Pharmacology and Experimental Therapeutics. 323: 738-45. PMID 17693585 DOI: 10.1124/Jpet.107.126888  0.432
2007 Alburges ME, Hoonakker AJ, Hanson GR. Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system European Journal of Pharmacology. 573: 124-132. PMID 17689525 DOI: 10.1016/J.Ejphar.2007.06.063  0.497
2007 Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ. Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology. 53: 447-54. PMID 17688891 DOI: 10.1016/J.Neuropharm.2007.06.009  0.398
2007 Riddle EL, Hanson GR, Fleckenstein AE. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. European Journal of Pharmacology. 571: 25-8. PMID 17618619 DOI: 10.1016/J.Ejphar.2007.05.044  0.46
2007 Volz TJ, Fleckenstein AE, Hanson GR. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction (Abingdon, England). 102: 44-8. PMID 17493052 DOI: 10.1111/J.1360-0443.2007.01771.X  0.521
2007 Frankel PS, Hoonakker AJ, Danaceau JP, Hanson GR. Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine. Pharmacology, Biochemistry, and Behavior. 86: 511-5. PMID 17303233 DOI: 10.1016/J.Pbb.2007.01.012  0.378
2007 Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. Journal of Neurochemistry. 101: 883-8. PMID 17250674 DOI: 10.1111/J.1471-4159.2006.04419.X  0.519
2007 Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology. 47: 681-98. PMID 17209801 DOI: 10.1146/Annurev.Pharmtox.47.120505.105140  0.472
2006 Rau KS, Truong JG, Wilkins DG, Fleckenstein AE, Hanson GR. Age-dependent effects of methamphetamine on VMAT-2. Annals of the New York Academy of Sciences. 1074: 154-9. PMID 17105913 DOI: 10.1196/Annals.1369.015  0.445
2006 Volz TJ, Hanson GR, Fleckenstein AE. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse (New York, N.Y.). 60: 474-7. PMID 16897727 DOI: 10.1002/Syn.20321  0.457
2006 Horner KA, Westwood SC, Hanson GR, Keefe KA. Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism. The Journal of Pharmacology and Experimental Therapeutics. 319: 414-21. PMID 16840646 DOI: 10.1124/Jpet.106.106856  0.427
2006 Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. The Aaps Journal. 8: E413-8. PMID 16808044 DOI: 10.1007/Bf02854914  0.399
2006 Rau KS, Birdsall E, Volz TJ, Riordan JA, Baucum AJ, Adair BP, Bitter R, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake. The Journal of Pharmacology and Experimental Therapeutics. 318: 676-82. PMID 16687477 DOI: 10.1124/Jpet.105.099200  0.551
2006 Volz TJ, Hanson GR, Fleckenstein AE. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. Journal of Neuroscience Methods. 155: 109-15. PMID 16480775 DOI: 10.1016/J.Jneumeth.2006.01.002  0.448
2005 Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. The Aaps Journal. 7: E847-51. PMID 16594636 DOI: 10.1208/Aapsj070481  0.496
2005 Frankel PS, Hoonakker AJ, Hanson GR, Bush L, Keefe KA, Alburges ME. Differential neurotensin responses to low and high doses of methamphetamine in the terminal regions of striatal efferents. European Journal of Pharmacology. 522: 47-54. PMID 16199030 DOI: 10.1016/J.Ejphar.2005.08.036  0.446
2005 Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology. 49: 820-30. PMID 16005476 DOI: 10.1016/J.Neuropharm.2005.05.004  0.54
2005 Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics. 314: 1087-92. PMID 15901804 DOI: 10.1124/Jpet.105.085951  0.507
2005 Horner KA, Adams DH, Hanson GR, Keefe KA. Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience. 131: 67-77. PMID 15680692 DOI: 10.1016/J.Neuroscience.2004.10.030  0.4
2005 Adams DH, Hanson GR, Keefe KA. 3,4-Methylenedioxymethamphetamine increases neuropeptide messenger RNA expression in rat striatum. Brain Research. Molecular Brain Research. 133: 131-42. PMID 15661373 DOI: 10.1016/J.Molbrainres.2004.10.005  0.457
2004 Hanson GR, Sandoval V, Riddle E, Fleckenstein AE. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Annals of the New York Academy of Sciences. 1025: 146-50. PMID 15542712 DOI: 10.1196/Annals.1316.019  0.498
2004 Truong JG, Newman AH, Hanson GR, Fleckenstein AE. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. European Journal of Pharmacology. 504: 27-32. PMID 15507217 DOI: 10.1016/J.Ejphar.2004.09.049  0.515
2004 Hanson GR, Rau KS, Fleckenstein AE. The methamphetamine experience: a NIDA partnership. Neuropharmacology. 47: 92-100. PMID 15464128 DOI: 10.1016/J.Neuropharm.2004.06.004  0.479
2004 Truong JG, Hanson GR, Fleckenstein AE. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. European Journal of Pharmacology. 492: 143-7. PMID 15178358 DOI: 10.1016/J.Ejphar.2004.03.060  0.537
2004 Baucum AJ, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 3436-43. PMID 15056723 DOI: 10.1523/Jneurosci.0387-04.2004  0.523
2003 Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. European Journal of Pharmacology. 479: 283-9. PMID 14612158 DOI: 10.1016/J.Ejphar.2003.08.077  0.434
2003 Truong JG, Rau KS, Hanson GR, Fleckenstein AE. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. European Journal of Pharmacology. 474: 223-6. PMID 12921866 DOI: 10.1016/S0014-2999(03)02080-6  0.522
2003 Ugarte YV, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors. European Journal of Pharmacology. 472: 165-71. PMID 12871750 DOI: 10.1016/S0014-2999(03)01911-3  0.556
2003 Johnson-Davis KL, Hanson GR, Keefe KA. Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats. Neurotoxicity Research. 5: 273-81. PMID 12835119 DOI: 10.1007/Bf03033385  0.433
2003 Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. The Journal of Pharmacology and Experimental Therapeutics. 304: 1181-7. PMID 12604695 DOI: 10.1124/Jpet.102.045005  0.524
2003 Riddle EL, Rau KS, Topham MK, Hanson GR, Fleckenstein AE. Ceramide-induced alterations in dopamine transporter function. European Journal of Pharmacology. 458: 31-6. PMID 12498904 DOI: 10.1016/S0014-2999(02)02727-9  0.502
2003 Adams DH, Hanson GR, Keefe KA. Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix. Journal of Neurochemistry. 84: 87-93. PMID 12485404 DOI: 10.1046/J.1471-4159.2003.01507.X  0.445
2002 Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW, Hanson GR, Fleckenstein AE. Inhibitory effect of reserpine on dopamine transporter function. European Journal of Pharmacology. 456: 39-43. PMID 12450567 DOI: 10.1016/S0014-2999(02)02647-X  0.522
2002 Hanson GR, Bush L, Keefe KA, Alburges ME. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine. Journal of Neurochemistry. 82: 1171-8. PMID 12358764 DOI: 10.1046/J.1471-4159.2002.01053.X  0.399
2002 Johnson-Davis KL, Hanson GR, Keefe KA. Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. Journal of Neurochemistry. 82: 1472-9. PMID 12354295 DOI: 10.1046/J.1471-4159.2002.01095.X  0.424
2002 Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8705-10. PMID 12351745 DOI: 10.1523/Jneurosci.22-19-08705.2002  0.545
2002 Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. European Journal of Pharmacology. 449: 71-4. PMID 12163108 DOI: 10.1016/S0014-2999(02)01985-4  0.471
2002 Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. The Journal of Pharmacology and Experimental Therapeutics. 302: 497-501. PMID 12130707 DOI: 10.1124/Jpet.302.2.497  0.541
2002 Crosby MJ, Hanson JE, Fleckenstein AE, Hanson GR. Phencyclidine increases vesicular dopamine uptake. European Journal of Pharmacology. 438: 75-8. PMID 11906713 DOI: 10.1016/S0014-2999(02)01298-0  0.537
2002 Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics. 300: 1093-100. PMID 11861820 DOI: 10.1124/Jpet.300.3.1093  0.56
2002 Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE. Tolerance to the neurotoxic effects of methamphetamine in young rats. European Journal of Pharmacology. 435: 181-5. PMID 11821024 DOI: 10.1016/S0014-2999(01)01592-8  0.442
2001 Brown JM, Hanson GR, Fleckenstein AE. Cocaine-induced increases in vesicular dopamine uptake: Role of dopamine receptors Journal of Pharmacology and Experimental Therapeutics. 298: 1150-1153. PMID 11504813  0.422
2001 Alburges ME, Keefe KA, Hanson GR. Unique responses of limbic met-enkephalin systems to low and high doses of methamphetamine. Brain Research. 905: 120-6. PMID 11423086 DOI: 10.1016/S0006-8993(01)02514-8  0.449
2001 Adams DH, Hanson GR, Keefe KA. Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience. 102: 843-51. PMID 11182247 DOI: 10.1016/S0306-4522(00)00530-3  0.373
2001 Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants Journal of Pharmacology and Experimental Therapeutics. 296: 762-767. PMID 11181904  0.416
2001 Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 1413-9. PMID 11160413 DOI: 10.1523/Jneurosci.21-04-01413.2001  0.517
2001 Alburges ME, Keefe KA, Hanson GR. Contrasting responses by basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model. Journal of Neurochemistry. 76: 721-9. PMID 11158242 DOI: 10.1046/J.1471-4159.2001.00043.X  0.453
2000 Sandoval V, Hanson GR, Fleckenstein AE. Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine. European Journal of Pharmacology. 409: 265-71. PMID 11108820 DOI: 10.1016/S0014-2999(00)00871-2  0.549
2000 Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. The Journal of Pharmacology and Experimental Therapeutics. 295: 1077-85. PMID 11082443  0.788
2000 Kokoshka JM, Fleckenstein AE, Wilkins DG, Hanson GR. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine Journal of Neurochemistry. 75: 2095-2102. PMID 11032899 DOI: 10.1046/J.1471-4159.2000.0752095.X  0.455
2000 Adams DH, Hanson GR, Keefe KA. Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum. Journal of Neurochemistry. 75: 2061-70. PMID 11032895 DOI: 10.1046/J.1471-4159.2000.0752061.X  0.4
2000 Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity European Journal of Pharmacology. 406: 1-13. PMID 11011026 DOI: 10.1016/S0014-2999(00)00639-7  0.462
2000 Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR. The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. Journal of Neurochemistry. 75: 1608-17. PMID 10987842 DOI: 10.1046/J.1471-4159.2000.0751608.X  0.793
2000 Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake Journal of Neurochemistry. 74: 2221-2223. PMID 10800970 DOI: 10.1046/J.1471-4159.2000.0742221.X  0.542
2000 Haughey HM, Brown JM, Wilkins DG, Hanson GR, Fleckenstein AE. Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Research. 863: 59-65. PMID 10773193 DOI: 10.1016/S0006-8993(00)02094-1  0.768
2000 Alburges ME, Ramos BP, Bush L, Hanson GR. Responses of the extrapyramidal and limbic substance P systems to ibogaine and cocaine treatments. European Journal of Pharmacology. 390: 119-26. PMID 10708715 DOI: 10.1016/S0014-2999(99)00919-X  0.438
2000 Bush L, McCabe T, Hanson GR. Selective antagonism of nigral neuropeptide responses to methamphetamine by conantokin G, a naturally occurring conopeptide. European Journal of Pharmacology. 387: 55-8. PMID 10633160 DOI: 10.1016/S0014-2999(99)00806-7  0.41
1999 Alburges ME, Hanson GR. Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine Brain Research. 847: 139-142. PMID 10564747 DOI: 10.1016/S0006-8993(99)02017-X  0.446
1999 Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, Gibb JW, Hanson GR. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. European Journal of Pharmacology. 382: 45-9. PMID 10556503 DOI: 10.1016/S0014-2999(99)00588-9  0.787
1999 Haughey HM, Brown JM, Fleckenstein AE, Hanson GR. Oxygen radicals differentially affect Na+/Cl(-)-dependent transporters. European Journal of Pharmacology. 379: 107-10. PMID 10499378 DOI: 10.1016/S0014-2999(99)00487-2  0.748
1999 Hanson GR, Jensen M, Johnson M, White HS. Distinct features of seizures induced by cocaine and amphetamine analogs. European Journal of Pharmacology. 377: 167-73. PMID 10456426 DOI: 10.1016/S0014-2999(99)00419-7  0.313
1999 Hiroi N, Fienberg AA, Haile CN, Alburges M, Hanson GR, Greengard P, Nestler EJ. Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. The European Journal of Neuroscience. 11: 1114-8. PMID 10103106 DOI: 10.1046/J.1460-9568.1999.00570.X  0.389
1999 Hanson GR, Keefe KA. Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway. Brain Research. Molecular Brain Research. 66: 111-21. PMID 10095083 DOI: 10.1016/S0169-328X(99)00033-9  0.48
1999 Westwood SC, Hanson GR. Effects of stimulants of abuse on extrapyramidal and limbic neuropeptide Y systems Journal of Pharmacology and Experimental Therapeutics. 288: 1160-1166. PMID 10027854  0.42
1999 Haughey HM, Fleckenstein AE, Hanson GR. Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. Journal of Neurochemistry. 72: 661-8. PMID 9930738 DOI: 10.1046/J.1471-4159.1999.0720661.X  0.738
1999 Alburges ME, Hanson GR. Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine Brain Research. 818: 96-104. PMID 9914442 DOI: 10.1016/S0006-8993(98)01206-2  0.492
1998 Hanson GR, Gibb JW, Metzger RR, Kokoshka JM, Fleckenstein AE. Methamphetamine-Induced Rapid and Reversible Reduction in the Activities of Tryptophan Hydroxylase and Dopamine Transporters: Oxidative Consequences?(a). Annals of the New York Academy of Sciences. 844: 103-107. PMID 29090817 DOI: 10.1111/J.1749-6632.1998.Tb08225.X  0.474
1998 Kokoshka JM, Vaughan RA, Hanson GR, Fleckenstein AE. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters European Journal of Pharmacology. 361: 269-275. PMID 9865517 DOI: 10.1016/S0014-2999(98)00741-9  0.504
1998 Metzger RR, Hanson GR, Gibb JW, Fleckenstein AE. 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. European Journal of Pharmacology. 349: 205-10. PMID 9671099 DOI: 10.1016/S0014-2999(98)00196-4  0.54
1998 Kokoshka JM, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Research. 799: 78-83. PMID 9666084 DOI: 10.1016/S0006-8993(98)00472-7  0.47
1998 Hanson GR, Wagstaff JD, Merchant K, Gibb JW. Psychostimulants and neuropeptide response. Advances in Pharmacology (San Diego, Calif.). 42: 1014-6. PMID 9328070 DOI: 10.1016/S1054-3589(08)60919-9  0.454
1997 Gygi MP, Fleckenstein AE, Gibb JW, Hanson GR. Role of endogenous dopamine in the neurochemical deficits induced by methcathinone Journal of Pharmacology and Experimental Therapeutics. 283: 1350-1355. PMID 9400010  0.464
1997 Gibb JW, Bush L, Hanson GR. Exacerbation of methamphetamine-induced neurochemical deficits by melatonin. The Journal of Pharmacology and Experimental Therapeutics. 283: 630-5. PMID 9353379  0.45
1997 Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, Hanson GR. Oxygen radicals diminish dopamine transporter function in rat striatum European Journal of Pharmacology. 334: 111-114. PMID 9346337 DOI: 10.1016/S0014-2999(97)01175-8  0.473
1997 Huang W, Hanson GR. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems European Journal of Pharmacology. 332: 15-21. PMID 9298921 DOI: 10.1016/S0014-2999(97)01032-7  0.503
1997 Fleckenstein AE, Beyeler ML, Jackson JC, Wilkins DG, Gibb JW, Hanson GR. Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters. European Journal of Pharmacology. 324: 179-86. PMID 9145769 DOI: 10.1016/S0014-2999(97)00081-2  0.5
1997 Fleckenstein AE, Metzger RR, Gibb JW, Hanson GR. A rapid and reversible change in dopamine transporters induced by methamphetamine European Journal of Pharmacology. 323: R9-R10. PMID 9128855 DOI: 10.1016/S0014-2999(97)00148-9  0.53
1997 Wagstaff JD, Gibb JW, Hanson GR. Role of dopamine D1- and NMDA receptors in regulating neurotensin release in the striatum and nucleus accumbens Brain Research. 748: 241-244. PMID 9067469 DOI: 10.1016/S0006-8993(96)01380-7  0.453
1997 Hanson GR, Bush LG, Taylor VL, Gibb JW, Davis K, Schmidt CJ. Comparison of neurotensin responses to MDL 100,907, a selective 5HT2A antagonist, with clozapine and haloperidol. Brain Research Bulletin. 42: 211-9. PMID 8995332 DOI: 10.1016/S0361-9230(96)00258-4  0.384
1996 Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR. Mechanisms for tolerance to methamphetamine effects. Neuropharmacology. 35: 751-757. PMID 8887984 DOI: 10.1016/0028-3908(96)84647-8  0.416
1996 Wagstaff JD, Gibb JW, Hanson GR. Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis Brain Research. 721: 196-203. PMID 8793101 DOI: 10.1016/0006-8993(96)00132-1  0.478
1996 Wagstaff JD, Gibb JW, Hanson GR. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens Journal of Pharmacology and Experimental Therapeutics. 278: 547-554. PMID 8768703  0.429
1995 Che S, Johnson M, Hanson GR, Gibb JW. Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity European Journal of Pharmacology: Environmental Toxicology And. 293: 447-453. PMID 8748698 DOI: 10.1016/0926-6917(95)90065-9  0.377
1995 Hanson GR, Singh N, Merchant K, Johnson M, Gibb JW. The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug and Alcohol Dependence. 37: 107-10. PMID 7758400 DOI: 10.1016/0376-8716(94)01065-S  0.423
1995 Hanson GR, Midgley LP, Bush LG, Gibb JW. Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment. European Journal of Pharmacology. 278: 167-73. PMID 7672001 DOI: 10.1016/0014-2999(95)00127-7  0.491
1995 Kralios FA, Anderson FL, Hanson GR, Kralios AC. Myocardial electrophysiological effects of neuropeptide Y in dogs. The American Journal of Physiology. 268: H2195-201. PMID 7611469 DOI: 10.1152/Ajpheart.1995.268.6.H2195  0.302
1994 Merchant KM, Hanson GR, Dorsa DM. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects. The Journal of Pharmacology and Experimental Therapeutics. 269: 806-12. PMID 8182549  0.311
1994 Gygi SP, Gibb JW, Hanson GR. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions Journal of Pharmacology and Experimental Therapeutics. 270: 192-197. PMID 7913495  0.396
1994 Midgley LP, Wagstaff JD, Singh NA, Bush LG, Gibb JW, Hanson GR. Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. European Journal of Pharmacology. 251: 191-9. PMID 7908639 DOI: 10.1016/0014-2999(94)90400-6  0.455
1994 Wagstaff JD, Bush LG, Gibb JW, Hanson GR. Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Research. 665: 237-44. PMID 7895059 DOI: 10.1016/0006-8993(94)91343-9  0.529
1994 Johnson M, Hanson GR, Gibb JW, Adair J, Filloux F. Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats. Developmental Brain Research. 83: 109-118. PMID 7535199 DOI: 10.1016/0165-3806(94)90184-8  0.393
1993 Midgley LP, Bush LG, Gibb JW, Hanson GR. Differential regulation of neuropeptide Y systems in limbic structures of the rat. The Journal of Pharmacology and Experimental Therapeutics. 267: 707-13. PMID 8246145  0.349
1993 Elkins KW, Gibb JW, Hanson GR, Wilkins DG, Johnson M. Effects of nimodipine on the amphetamine- and methamphetamine-induced decrease in tryptophan hydroxylase activity European Journal of Pharmacology. 250: 395-402. PMID 8112400 DOI: 10.1016/0014-2999(93)90026-E  0.457
1993 Johnson M, Bush LG, Hanson GR, Gibb JW. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations. Biochemical Pharmacology. 46: 770-2. PMID 8103327 DOI: 10.1016/0006-2952(93)90568-H  0.428
1993 Gygi SP, Gibb JW, Johnson M, Hanson GR. Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats European Journal of Pharmacology. 250: 177-180. PMID 7509751 DOI: 10.1016/0014-2999(93)90639-Y  0.503
1993 Dinger B, Wang Z-, Chen J, Wang W-, Hanson G, Stensaas LJ, Fidone SJ. Immunocytochemical and neurochemical aspects of sympathetic ganglion chemosensitivity. Advances in Experimental Medicine and Biology. 337: 25-30. DOI: 10.1007/978-1-4615-2966-8_4  0.374
1992 Johnson M, Bush LG, Midgley L, Gibb JW, Hanson GR. MK-801 blocks the changes in neurotensin concentrations induced by methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, and GBR 12909. Annals of the New York Academy of Sciences. 668: 350-2. PMID 1463283 DOI: 10.1111/J.1749-6632.1992.Tb27373.X  0.355
1992 Hanson GR, Singh N, Merchant K, Johnson M, Bush L, Gibb JW. Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms. Annals of the New York Academy of Sciences. 668: 165-72. PMID 1361111 DOI: 10.1111/J.1749-6632.1992.Tb27348.X  0.417
1992 Midgley LP, Bush LG, Gibb JW, Hanson GR. Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen. Brain Research. 593: 89-96. PMID 1360868 DOI: 10.1016/0006-8993(92)91268-J  0.474
1992 Elayan I, Gibb JW, Hanson GR, Foltz RL, Lim HK, Johnson M. Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or2-hydroxy-4,5-methylenedioxyamphetamine European Journal of Pharmacology. 221: 281-288. PMID 1358654 DOI: 10.1016/0014-2999(92)90714-F  0.392
1992 Hanson GR, Bunker CF, Johnson M, Bush L, Gibb JW. Response of monoaminergic and neuropeptide systems to 4-methylaminorex: a new stimulant of abuse. European Journal of Pharmacology. 218: 287-93. PMID 1358636 DOI: 10.1016/0014-2999(92)90181-3  0.482
1992 Singh NA, Bush LG, Gibb JW, Hanson GR. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Brain Research. 571: 260-4. PMID 1351780 DOI: 10.1016/0006-8993(92)90663-T  0.375
1992 Anderson FL, Port JD, Reid BB, Larrabee P, Hanson G, Bristow MR. Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta-adrenergic receptor downregulation. Circulation. 85: 46-53. PMID 1309447 DOI: 10.1161/01.Cir.85.1.46  0.373
1991 Hanson GR, Singh N, Bush L, Gibb JW. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 259: 1197-202. PMID 1722253  0.356
1991 Johnson M, Hanson GR, Gibb JW. Norepinephrine does not contribute to methamphetamine-induced changes in hippocampal serotonergic system Neuropharmacology. 30: 617-622. PMID 1717871 DOI: 10.1016/0028-3908(91)90081-L  0.427
1991 Singh NA, Midgley LP, Bush LG, Gibb JW, Hanson GR. N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems. Brain Research. 555: 233-8. PMID 1681999 DOI: 10.1016/0006-8993(91)90346-W  0.412
1991 Johnson M, Bush LG, Gibb JW, Hanson GR. Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems. European Journal of Pharmacology. 193: 367-70. PMID 1675997 DOI: 10.1016/0014-2999(91)90153-H  0.48
1990 Singh NA, Bush LG, Gibb JW, Hanson GR. Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors. European Journal of Pharmacology. 187: 337-44. PMID 2150044 DOI: 10.1016/0014-2999(90)90361-9  0.435
1990 Merchant KM, Bush LG, Gibb JW, Hanson GR. Neurotensin-dopamine interactions in the substantia nigra of the rat brain. The Journal of Pharmacology and Experimental Therapeutics. 255: 775-80. PMID 2147039  0.398
1990 Gibb JW, Johnson M, Hanson GR. Neurochemical basis of neurotoxicity Neurotoxicology. 11: 317-321. PMID 1978271  0.409
1990 Bunker CF, Johnson M, Gibb JW, Bush LG, Hanson GR. Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse. European Journal of Pharmacology. 180: 103-11. PMID 1973111 DOI: 10.1016/0014-2999(90)90597-Y  0.466
1990 Gibb JW, Mitros K, Hanson GR, Johnson M. Flunarizine blocks the decrease in tryptophan hydroxylase activity induced by 3,4-methylenedioxymethamphetamine European Journal of Pharmacology. 183: 1916. DOI: 10.1016/0014-2999(90)92260-P  0.335
1989 Stone DM, Johnson M, Hanson GR, Gibb JW. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites European Journal of Pharmacology: Molecular Pharmacology. 172: 93-97. PMID 2714371 DOI: 10.1016/0922-4106(89)90048-5  0.403
1989 Hanson GR, Smiley P, Johnson M, Letter A, Bush L, Gibb JW. Response by the neurotensin systems of the basal ganglia to cocaine treatment. European Journal of Pharmacology. 160: 23-30. PMID 2714362 DOI: 10.1016/0014-2999(89)90650-X  0.474
1989 Matsuda LA, Hanson GR, Gibb JW. Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems Journal of Pharmacology and Experimental Therapeutics. 251: 901-908. PMID 2600821  0.369
1989 Johnson M, Hanson GR, Gibb JW. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog European Journal of Pharmacology. 165: 315-318. PMID 2570704 DOI: 10.1016/0014-2999(89)90728-0  0.412
1989 Stone DM, Hanson GR, Gibb JW. In Vitro Reactivation of Rat Cortical Tryptophan Hydroxylase Following In Vivo Inactivation by Methylenedioxymethamphetamine Journal of Neurochemistry. 53: 572-581. PMID 2568404 DOI: 10.1111/J.1471-4159.1989.Tb07372.X  0.339
1989 Merchant KM, Gibb JW, Hanson GR. Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens European Journal of Pharmacology. 160: 409-412. PMID 2565819 DOI: 10.1016/0014-2999(89)90098-8  0.446
1989 Merchant KM, Bush LG, Gibb JW, Hanson GR. Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain. Brain Research. 500: 21-9. PMID 2532557 DOI: 10.1016/0006-8993(89)90295-3  0.521
1989 Gibb JW, Stone DM, Johnson M, Hanson GR. Role of dopamine in the neurotoxicity induced by amphetamines and related designer drugs Nida Research Monograph. 94: 161-178. PMID 2514363  0.321
1989 Johnson M, Hanson GR, Gibb JW. Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system Biochemical Pharmacology. 38: 4333-4338. PMID 2480796 DOI: 10.1016/0006-2952(89)90534-0  0.37
1989 Johnson M, Stone DM, Bush LG, Hanson GR, Gibb JW. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. European Journal of Pharmacology. 161: 181-8. PMID 2470597 DOI: 10.1016/0014-2999(89)90841-8  0.408
1988 Johnson M, Hanson GR, Gibb JW. Effects of dopaminergic and serotonergic receptor blockade on neurochemical changes induced by acute administration of methamphetamine and 3,4-methylenedioxymethamphetamine Neuropharmacology. 27: 1089-1096. PMID 3144655 DOI: 10.1016/0028-3908(88)90002-0  0.417
1988 Hanson GR, Merchant KM, Letter AA, Bush L, Gibb JW. Characterization of methamphetamine effects on the striatal-nigral dynorphin system. European Journal of Pharmacology. 155: 11-8. PMID 2907484 DOI: 10.1016/0014-2999(88)90397-4  0.514
1988 Merchant KM, Letter AA, Gibb JW, Hanson GR. Changes in the limbic neurotensin systems induced by dopaminergic drugs European Journal of Pharmacology. 153: 1-9. PMID 2905662 DOI: 10.1016/0014-2999(88)90581-X  0.512
1988 Stone DM, Johnson M, Hanson GR, Gibb JW. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine Journal of Pharmacology and Experimental Therapeutics. 247: 79-87. PMID 2902215  0.446
1988 McCabe RT, Hanson GR, Dawson TM, Wamsley JK, Gibb JW. Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity. Neuroscience. 23: 253-61. PMID 2891082 DOI: 10.1016/0306-4522(87)90287-9  0.415
1988 Matsuda LA, Schmidt CJ, Gibb JW, Hanson GR. Effects of methamphetamine on central monoaminergic systems in normal and ascorbic acid-deficient guinea pigs Biochemical Pharmacology. 37: 3477-3484. PMID 2458731 DOI: 10.1016/0006-2952(88)90700-9  0.435
1987 Letter AA, Matsuda LA, Merchant KM, Gibb JW, Hanson GR. Characterization of dopaminergic influence on striatal-nigral neurotensin systems. Brain Research. 422: 200-203. PMID 3119151 DOI: 10.1016/0006-8993(87)90560-9  0.495
1987 Stone DM, Merchant KM, Hanson GR, Gibb JW. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat Neuropharmacology. 26: 1677-1683. PMID 2893986 DOI: 10.1016/0028-3908(87)90117-1  0.446
1987 Hanson GR, Merchant KM, Letter AA, Bush L, Gibb JW. Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors. European Journal of Pharmacology. 144: 245-6. PMID 2893739 DOI: 10.1016/0014-2999(87)90527-9  0.329
1987 Tyler McCabe R, Gibb JW, Wamsley JK, Hanson GR. Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment Brain Research Bulletin. 19: 551-557. PMID 2891416 DOI: 10.1016/0361-9230(87)90072-4  0.366
1987 Merchant KM, Letter AA, Johnson M, Stone DM, Gibb JW, Hanson GR. Effects of amphetamine analogs on neurotensin concentrations in rat brain. European Journal of Pharmacology. 138: 151-154. PMID 2887434 DOI: 10.1016/0014-2999(87)90353-0  0.471
1987 Hanson GR, Matsuda LA, Gibb JW. Effects of cocaine on methamphetamine-induced neurochemical changes: Characterization of cocaine as a monoamine uptake blocker Journal of Pharmacology and Experimental Therapeutics. 242: 507-513. PMID 2886643  0.337
1987 Johnson M, Stone DM, Hanson GR, Gibb JW. Role of the dopaminergic nigrostriatal pathway in methamphetamine-induced depression of the neostriatal serotonergic system European Journal of Pharmacology. 135: 231-234. PMID 2884120 DOI: 10.1016/0014-2999(87)90616-9  0.462
1987 Stone DM, Johnson M, Hanson GR, Gibb JW. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives European Journal of Pharmacology. 134: 245-248. PMID 2883012 DOI: 10.1016/0014-2999(87)90173-7  0.329
1987 Gibb JW, Stone DM, Stahl DC, Hanson GR. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain Nida Research Monograph. 76: 316-321. PMID 2449619  0.414
1987 Stone DM, Hanson GR, Gibb JW. Differences in the central serotonergic effects of Methylenedioxymethamphetamine (MDMA) in mice and rats Neuropharmacology. 26: 1657-1661. PMID 2448703 DOI: 10.1016/0028-3908(87)90017-7  0.411
1987 Johnson M, Hanson GR, Gibb JW. Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat Biochemical Pharmacology. 36: 4085-4093. PMID 2446629 DOI: 10.1016/0006-2952(87)90565-X  0.476
1987 Matsuda LA, Schmidt CJ, Gibb JW, Hanson GR. Ascorbic acid-deficient condition alters central effects of methamphetamine Brain Research. 400: 176-180. PMID 2434185 DOI: 10.1016/0006-8993(87)90668-8  0.473
1986 Sonsalla PK, Gibb JW, Hanson GR. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems Journal of Pharmacology and Experimental Therapeutics. 238: 932-937. PMID 2943891  0.378
1986 Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain European Journal of Pharmacology. 128: 41-48. PMID 2875893 DOI: 10.1016/0014-2999(86)90555-8  0.528
1986 Matsuda LA, Schmidt CJ, Hanson GR, Gibb JW. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat Neuropharmacology. 25: 249-255. PMID 2871513 DOI: 10.1016/0028-3908(86)90247-9  0.48
1986 Hanson GR, Letter AA, Merchant K, Gibb JW. Comparison of responses by striatonigral substance P and neurokinin A systems to methamphetamine treatment Peptides. 7: 983-987. PMID 2436197 DOI: 10.1016/0196-9781(86)90125-7  0.38
1986 Sonsalla PK, Gibb JW, Hanson GR. Nigrostriatal dopamine actions on the D2 receptors mediate methamphetamine effects on the striatonigral substance P system Neuropharmacology. 25: 1221-1230. PMID 2432440 DOI: 10.1016/0028-3908(86)90139-5  0.495
1986 Hanson GR, Ritter JK, Schmidt CJ, Gibb JW. Response of mesolimbic substance P systems to methamphetamine treatment European Journal of Pharmacology. 128: 265-268. PMID 2431914 DOI: 10.1016/0014-2999(86)90775-2  0.361
1985 Ritter JK, Gehlert DR, Gibb JW, Wamsley JK, Hanson GR. Neuronal localization of substance P receptors in rat neostriatum European Journal of Pharmacology. 109: 431-432. PMID 2985407 DOI: 10.1016/0014-2999(85)90409-1  0.312
1985 Schmidt CJ, Gehlert DR, Peat MA, Sonsalla PK, Hanson GR, Wamsley JK, Gibb JW. Studies on the mechanism of tolerance to methamphetamine Brain Research. 343: 305-313. PMID 2413961 DOI: 10.1016/0006-8993(85)90748-6  0.471
1985 Ritter JK, Schmidt CJ, Gibb JW, Hanson GR. Dopamine-mediated increases in nigral substance P-like immunoreactivity Biochemical Pharmacology. 34: 3161-3166. PMID 2412564 DOI: 10.1016/0006-2952(85)90163-7  0.498
1984 Sonsalla PK, Gibb JW, Hanson GR. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation European Journal of Pharmacology. 105: 185-187. PMID 6208043 DOI: 10.1016/0014-2999(84)90666-6  0.361
1984 Ritter JK, Schmidt CJ, Gibb JW, Hanson GR. Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment Journal of Pharmacology and Experimental Therapeutics. 229: 487-492. PMID 6201607  0.378
1981 Pradhan S, Hanson G, Lovenberg W. Inverse relation of substance P-like immunoreactivity in dorsal raphe nucleus to serotonin levels in pons-medulla following administration of cocaine and 5-hydroxytryptophan Biochemical Pharmacology. 30: 1071-1076. PMID 6167271 DOI: 10.1016/0006-2952(81)90444-5  0.401
1981 Hanson G, Alphs L, Pradhan S, Lovenberg W. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist Neuropharmacology. 20: 541-548. PMID 6165922 DOI: 10.1016/0028-3908(81)90206-9  0.466
1980 Hanson GR, Lovenberg W. Elevation of Substance P‐like Immunoreactivity in Rat Central Nervous System by Protease Inhibitors Journal of Neurochemistry. 35: 1370-1374. PMID 6160206 DOI: 10.1111/J.1471-4159.1980.Tb09011.X  0.321
Show low-probability matches.